经产状态对初次乳房隆乳术的影响:一项临床与成本效益的病例对照研究
该研究回顾894例假体隆乳患者并用85例前瞻性队列比较经产与未产者的手术效率与成本效益。经产者平均手术时间35±6.3分钟,未产者30.2±5分钟,差异有统计学意义(p=0.0004,95%CI 2.2-7.4分钟)。经产与并发症发生率无显著差异(p=0.82)。
要点
- 经产者与未产者并发症发生率无显著差异(p=0.82)。
- 经产者平均手术时间较未产者增加4.8分钟(13.7%),p=0.0004。
- 经产状态可能影响手术效率与成本效益,但不影响并发症率。
核心结论
- 经产女性乳房实质与血管组织改变可能未完全恢复至孕前状态,影响手术效率与成本效益;在锐性精确剥离与主动止血技术下,经产不增加并发症率,但手术时间更长。
研究设计与样本
- 回顾性审查所有由单一术者经乳房下皱襞切口在全身麻醉下完成假体双侧初次乳房隆乳术的患者。
- 另进行前瞻性对比试验,由独立观察者记录85例连续队列患者的手术效率(总手术时间)与即刻并发症。
- 回顾性部分共纳入894例患者,术后至少随访6个月;前瞻性部分85例中经产54例、未产31例。
主要发现
- 894例中未产445例(49.8%),至少生育一胎449例(50.2%);平均产次指数1.05,平均BMI 20.8 kg/m2(15.9-30.8),平均假体体积314 ml。
- 术后并发症发生率15%(n=134),平均随访12.8(6-116)个月;经产与并发症发生率差异无统计学意义(p=0.82)。
- 经产者总手术时间35±6.3分钟,未产者30.2±5分钟;临床平均差异4.8分钟,最大差异16.1分钟。
- 经产者较未产者手术时间平均增加13.7%(p=0.0004,95%CI 2.2-7.4分钟)。
临床怎么用
- 作者认为经产状态可能影响手术效率与成本效益,但基于锐性精确剥离与主动止血技术,经产不增加并发症率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Breast augmentation is one of the most commonly performed aesthetic procedures in women. Despite the structural changes which occur during pregnancy and lactation have been extensively studied, there is no clarity in terms of the time required for the parenchymal angiogenic changes to regress or if these neovessels are preserved even years after the last lactating period. This study investigated whether these post-pregnancy structural changes on the breasts may influence the surgical efficiency, affect the rates of complications and have an impact on cost-effectiveness in primary breast augmentation. METHODS: This study encompasses a retrospective review of all patients who underwent implant-based bilateral primary breast augmentation, through inframammary fold (IMF) incision under general anaesthetic, by a single surgeon. The age, height, weight and parity (nulliparous or multiparous status), characteristics of implants used and clinical outcomes after a minimum of 6-month post-operative follow-up were recorded. A further prospective comparative trial investigated the effects of parity in the surgical efficiency and cost-effectiveness in primary breast augmentation. The surgical efficiency (total operative time) and the immediate complications of 85 consecutive cohort of patients were recorded by an independent observer. Statistical correlation investigated the relevance of parity as predictors of surgical efficiency and cost-effectiveness. RESULTS: A total of 894 patients were included with a minimum of 6-month follow-up following implants-based primary breast augmentation. There were 445 (49.8%) nulliparous and 449 (50.2%) patients had at least one child at the time of surgery. The average parity index was calculated to be 1.05. The average body mass index (BMI) was 20.8 kg/m2 (15.9-30.8). The mean implant volume used was 314 ml. Fifteen percent (n = 134) presented with post-operative complications, with an average follow-up period of 12.8 (6-116) months. The differences between parity and incidence of complications were not statistically significant (p = 0.82). Surgical efficiency parameters from 85 women (54 multiparous and 31 nulliparous) demonstrated total operative time difference; 35 ± 6.3 min for multiparous and 30.2 ± 5 min for nulliparous. There was a clinical average difference of 4.8 min, with a maximum difference of 16.1 min. These statistically significant difference account for an average increase of 13.7% in the operating time in multiparous versus nulliparous (p-value=0.0004, 95% CI = 2.2-7.4 min). CONCLUSION: Primary breast augmentation in parous women faces parenchymal and vascular histological breast tissue transformations which may not fully revert to the pre-pregnant state. These changes encountered during pocket dissection seem to have an impact on the operating time, cost-effectiveness and can therefore affect negatively surgical efficiency. Nevertheless, when surgical technique is based on sharp, precise dissection and proactive haemostasis, parity does not show to have an impact on the rates of complications, despite longer operation times.
引用
- Montemurro P, Pafitanis G, Asokan H, et al. The impact of parity in primary breast augmentation: A clinical and cost-effective case control study. J Plast Reconstr Aesthet Surg. 2022. PMID: 35317979. doi:10.1016/j.bjps.2022.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。